Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer
July 28, 2021 08:00 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease
March 08, 2021 13:00 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
Alkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease
January 28, 2021 08:00 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
Alkahest Provides Corporate Update
July 09, 2020 07:30 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairment in End Stage Renal Disease Patients
June 01, 2020 07:30 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290 in Patients with Treatment-Naïve Wet Age-Related Macular Degeneration
February 10, 2020 07:30 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation
February 04, 2020 07:30 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today...
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of AKST4290 on Choroidal Blood Flow in Age-Related Macular Degeneration
December 17, 2019 07:30 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today...
Alkahest Presents Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease
December 09, 2019 07:30 ET
|
Alkahest, Inc.
Clinical results presented Saturday, December 7th at CTAD 2019 Data support continued clinical development in randomized placebo controlled clinical trials SAN CARLOS, Calif., Dec. 09, 2019 ...
Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference
December 02, 2019 07:30 ET
|
Alkahest, Inc.
SAN CARLOS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...